timothy sykes logo
LABT Stock Whipsaws As Traders Eye Virtual Forum Exposure Thumbnail
G Google News

LABT Stock Whipsaws As Traders Eye Virtual Forum Exposure

BRYCE TUOHEY•UPDATED JUL. 22, 2026, 9:19 AM ET
Reviewed by Tim Sykesand Fact-checked by Matt Monaco

Lakewood-Amedex Biotherapeutics Inc. stocks have been trading up by 216.61 percent amid heightened optimism over its biotherapeutic pipeline.

Key Takeaways

  • A broad group of small and mid-cap life sciences names, including Lakewood-Amedex Biotherapeutics Inc. (LABT), joined the 2026/06/24–2026/06/25 Life Sciences Virtual Investor Forum.
  • The Virtual Investor Conferences/OTC Markets event gave LABT live presentation time plus access to 1×1 meetings with active traders.
  • Recordings from the June forum are now on-demand, and LABT-focused 1×1 meetings remain available for traders and analysts.
  • The forum’s focus on small-cap life sciences and med‑tech places LABT alongside other emerging healthcare stories targeting public market visibility.

Candlestick Chart

Live Update At 09:19:00 EDT: On Wednesday, July 22, 2026 Lakewood-Amedex Biotherapeutics Inc. stock [NASDAQ: LABT] is trending up by 216.61%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

LABT is trading like a classic thin, high‑risk biotech, with sharp moves and shaky fundamentals. Over the past couple of weeks, Lakewood-Amedex Biotherapeutics Inc. has slid from closes near $3.48 on 2026/06/29 down toward the $1.86 area on 2026/07/21. That’s a deep drawdown and shows how quickly momentum is shifting in LABT.

Intraday, LABT has been a wild ride. Pre‑market and early‑session action shows spikes from around $1.86 at 07:25 up through the $7s by 08:40, then fading back into the mid‑$5s and $6s. Those kinds of wicks tell traders two things: there is serious speculative interest, and liquidity can vanish just as fast as it appears.

More Breaking News

On the fundamentals, LABT is still early‑stage and burning cash. Lakewood-Amedex Biotherapeutics Inc. reported roughly -$0.2 basic EPS in Q1 2026, negative free cash flow around -$300,000, and a balance sheet with only about $11,700 in cash versus more than $3.0M in liabilities. A negative book value per share, around -$0.41, and extreme negative return on assets underline that LABT is a development‑stage story. For traders, that means any move is driven far more by sentiment, news, and liquidity than by traditional value metrics.

Why Traders Are Watching LABT’s Virtual Forum Push

LABT is not in the spotlight because of a trial win or an FDA headline. The attention today centers on visibility. Lakewood-Amedex Biotherapeutics Inc. joined a broad slate of small and mid‑cap life sciences companies at the Life Sciences Virtual Investor Forum on 2026/06/24–2026/06/25, hosted by Virtual Investor Conferences and OTC Markets. For a micro‑cap biotech like LABT, that kind of exposure is often the entire game.

Events like this don’t instantly change the balance sheet. What they can change is the audience. LABT now has its story recorded and available on‑demand, with traders able to replay management’s pitch and decide whether the science and roadmap justify the volatility on the chart. The continued option for 1×1 meetings means active small‑cap biotech traders and analysts can still drill into details directly with Lakewood-Amedex Biotherapeutics Inc.

For LABT, that slow drip of awareness can matter. When a name trades thin and has negative equity, the difference between nobody watching and a few hundred engaged traders is massive. The insane intraday swings in LABT—where pre‑market volume pushed the stock from sub‑$2 into the $7 area in less than two hours—fit perfectly with a story that is just beginning to reach a wider audience through forums like this.

Traders in the Tim Sykes community look for exactly this kind of setup: a speculative biotech, fresh exposure via an event, and a chart showing aggressive range expansion. LABT’s participation at the forum does not guarantee a sustained uptrend, but it gives the stock a narrative hook that chatrooms and scanners can latch onto. That alone can fuel extra liquidity and short‑term trading opportunities.

Conclusion

Lakewood-Amedex Biotherapeutics Inc. is still a high‑risk, development‑stage biotech trying to survive. The financials show heavy losses, negative book value, almost no cash cushion, and leverage that would frighten any long‑term holder. Yet LABT’s chart shows why traders keep coming back. Multi‑day action reveals a sharp drop from the mid‑$3s to below $2, while intraday prints show violent spikes into the $7 range. That combination of weak fundamentals, thin float dynamics, and new eyeballs from the Life Sciences Virtual Investor Forum is exactly what short‑term traders hunt.

LABT’s presence at the June virtual event, plus the ongoing on‑demand access and 1×1 meeting options, should keep a trickle of new traders looking at the name. Lakewood-Amedex Biotherapeutics Inc. now has a public stage to repeat its story, answer questions, and potentially attract the kind of speculative volume that drives its huge candles.

For anyone trading LABT, the playbook stays simple: watch the price action around news, track volume spikes when new traders discover the forum replay, and respect how fast these moves unwind. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only your plan.” As millionaire penny stock trader and teacher Tim Sykes, says, “Cut losses quickly, let profits ride, and don’t overtrade.”. Whether you’re going long on momentum or betting on backside fades, LABT demands a clear plan, tight risk, and the discipline to cut losses quickly. This coverage is for educational and research purposes only, not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”